Browse the evidence

Further studies are needed to better evaluate and refine the efficacy of technology-based WLMIs.

Ongoing research is essential for improving the effectiveness of technology-based weight loss interventions.

Obesity is a disorder of energy metabolism characterized by low usable energy (ATP) in the setting of elevated total energy.

Practitioners should consider the role of energy metabolism in obesity management.

Treatment response heterogeneity is an important area of research in personalized and precision medicine.

Researchers should focus on understanding individual responses to treatments in nutrition and obesity.

Financial incentives, environmental change strategies, and their combination were not significantly more effective than usual care.

Practitioners should consider that these interventions may not provide significant advantages over standard care.

New pharmacological treatments for obstructive sleep apnea (OSA) might be effective.

Practitioners should consider new pharmacological options for treating OSA.

There is a need to develop new cost-effective strategies for OSA management.

Practitioners should consider implementing innovative and cost-effective strategies for managing OSA.

Sustained remission was observed in 15.8 % (n = 19) over three years and in 12.5 % (n = 15) over four years.

Sustained remission can be a realistic goal for patients on a very low carbohydrate diet.

Tirzepatide, a GLP-1/GIP receptor co-agonist, was approved by the FDA for the treatment of T2DM and provides superior HbA1c reductions.

Healthcare providers can utilize tirzepatide as a more effective treatment option for T2DM.

Less than half of obese patients were considering weight loss in the coming month.

Practitioners should address motivation and readiness to change in obese CHD patients.

The safety profile of tirzepatide is consistent across all phase 3 trials.

Practitioners can expect a consistent safety profile when prescribing tirzepatide.

Effect sizes of GLP-1 receptor agonists in schizophrenia are mostly smaller than in the general population.

While GLP-1 receptor agonists can aid in weight loss, practitioners should manage expectations regarding the magnitude of effect in this population.

Future trials of GLP-1 receptor agonists could focus on dual or triple agonist agents.

Exploring dual or triple agonist therapies may enhance treatment options for weight management in schizophrenia.

Subjects trained in record keeping did not differ from untrained subjects in terms of energy intake reporting accuracy.

Training in dietary record keeping may not improve the accuracy of self-reported intake.

The SLOW group reported a higher rating of perceived exertion (RPE) than the FAST group.

Strength and conditioning professionals should consider RPE when designing training programs with different tempos.

A semisupervised high-intensity interval training (HIT) intervention did not increase menstrual frequency in women with PCOS after 12 months.

Practitioners should note that HIT may not improve menstrual frequency in women with PCOS.

Protein supplementation does not significantly augment the effects of resistance exercise training on muscle mass or strength in older adults (≥70 years) compared to resistance exercise alone.

If you are over 70 and doing resistance training, you do not need to buy protein supplements to get better results. The research shows that getting protein from food is just as effective as supplements for building muscle and strength in this age group. Focus on eating enough protein overall rather than spending money on powders.

Preoperative insulin therapy and T2DM duration ≥5 years were predictors of less favorable outcomes.

Consideration of insulin therapy and diabetes duration is crucial for predicting surgical outcomes.

MYOD1, MYF5, and MYF6 mean methylation was reduced after 4 and 8 hours in response to all exercise protocols.

Resistance, high-intensity interval, and concurrent exercise can effectively reduce DNA methylation in myogenic regulatory factors.

Changes in DNA methylation and mRNA expression were largely confined to the late (4-8 h) recovery period.

Recovery periods after exercise are critical for observing changes in muscle regulatory factors.

Lesser known factors such as cerebral blood flow, food cue reactivity, gut hormone levels, and dietary adherence possibly impact variability of response to liraglutide.

Healthcare providers should consider these lesser-known factors when evaluating patient responses to liraglutide.

Ten proteins were associated with different rates of weight regain, some specifying pathways of chemotaxis and innate immune responses.

Identifying specific proteins may help tailor interventions for weight regain.

24% of patients with diabetes and delayed gastric emptying were on a GLP-1 receptor agonist.

Practitioners should be aware that a notable percentage of diabetic patients with delayed gastric emptying are using GLP-1R agonists.

GLP-1 receptor agonists use was associated with delayed gastric emptying in patients with diabetes for less than 10 years.

Clinicians should consider the duration of diabetes when prescribing GLP-1R agonists.

The study could not establish statistical significance regarding the likelihood of delayed gastric emptying in patients on GLP-1R agonists.

Further research is needed to clarify the relationship between GLP-1R agonists and gastric emptying.